Short-acting β2-agonist use and asthma exacerbations in Swedish children : A SABINA Junior study
Background: In adults and adolescents with asthma, use of ≥3 short-acting β2-agonist (SABA) canisters/year is associated with increased exacerbation risk. Whether this association is present in younger children remains unknown. In this SABA use IN Asthma (SABINA) Junior study, we assessed the association of SABA collection with exacerbation risk in the general Swedish pediatric asthma population.
